October 24th 2024
Nina Vadiei, PharmD, BCPP, a clinical associate professor at UT Austin and a clinical pharmacy specialist in psychiatry at San Antonio State Hospital, discusses her career as a psychiatric pharmacist.
Small study shows benefit of warfarin for cluster headaches
July 15th 2011Chronic cluster headaches are debilitating for patients who experience them. A recent study concluded that low-intensity anticoagulation with warfarin was associated with significantly higher incidence of remission and less headache impact on patients' lives.
Elderly cancer patients at risk for adverse drug reactions, interactions
July 13th 2011Polypharmacy is becoming a greater risk factor for elderly cancer patients, resulting in an increased risk of adverse drug reactions and drug interactions, according to a recent study published in The Lancet Oncology.
Drug shortages have huge impact on health systems, Congress told
July 13th 2011According to a briefing presented to Congress on Tuesday, drug shortages are having an enormous impact on the nation's health systems through delayed treatment, less effective drug treatments provided to patients, and increased drug costs.
Duane Reade opens flagship store on Wall Street
July 12th 2011Duane Reade?s new flagship store on Wall Street in New York City features sushi chefs and a new connection to Walgreens? pharmacy network. The Duane Reade store signals a prototype for future Duane Reade stores. Duane Reade is owned by Walgreens and has more than 250 stores in the New York City region.
Low vitamin D levels associated with diabetes; supplementation trials needed
July 12th 2011New studies confirm that lower levels of vitamin D are associated with a higher risk of diabetes and diabetic retinopathy. But the mechanisms by which vitamin D may affect progression, beta cell function, dysglycemia, and retinopathy are not clear.
Low-cost generics a mixed blessing for diabetes treatment
July 12th 2011Low-cost generic drug programs pioneered by Wal-Mart and other big-box retailers are a mixed blessing for patients with diabetes. The loss-leader strategy used by big-box, chain, independent, and online pharmacies has boosted the mean cost of branded diabetes medications by up to 113% since 2008.
Innovative program establishes pharmacist as health coach, partner
July 12th 2011David D. Pope, PharmD, CDE, editor-in-chief of CreativePharmacist.com, has developed and directs an innovative, web-based program titled HealthyHeartClub.com, which offers accountability, encouragement, and education to help patients adopt healthier lifestyles and decrease cardiovascular risk.
Breaking news: FDA approves Boostrix to help prevent whooping cough in older adults
July 11th 2011FDA has approved Boostrix [Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed (Tdap); GlaxoSmithKline Biologicals] for use in adults aged 65 years and older for active booster immunization against tetanus, diphtheria, and pertussis (whooping cough). This approval makes Boostrix the first Tdap vaccine approved for use by this age group.
Breaking news: Multaq phase 3 study halts; increased cardiovascular events cited
July 8th 2011Dronedarone (Multaq, Sanofi), which is approved for nonpermanent atrial fibrillation (AF), was being tested on patients with permanent AF. However, that trial, PALLAS (Permanent Atrial fibrillation outcome Study using Dronedarone on top of standard therapy) phase 3b, has been terminated because it was causing increased cardiovascular events.
New evidence-based guidelines for PDN treatment
July 6th 2011In an effort to address the efficacy of various treatment options available to reduce pain and improve physical function and quality of life in patients with painful diabetic neuropathy, a broad literature review was conducted and new guidelines were published online May 17 in Neurology and were presented at the American Academy of Neurology Annual Meeting in Honolulu.
FDA approves Xarelto to help prevent DVT in patients undergoing knee- or hip-replacement surgery
July 6th 2011FDA has approved rivaroxaban tablets (Xarelto, Janssen Pharmaceuticals), a novel, once-daily, oral anticoagulant for the prevention (prophylaxis) of deep vein thrombosis (DVT), which may lead to a pulmonary embolism (PE) in people undergoing knee- or hip-replacement surgery. Xarelto is the only new oral anticoagulant with FDA approval for this indication.
Senate Community Pharmacy Caucus formed
July 6th 2011The first Senate Community Pharmacy Caucus was established in late June. Senator Jerry Moran (R-KS) and Senator Jon Tester (D-MT) created the caucus, which is meant to serve as an advocate for community pharmacy issues and as a clearinghouse of information for senators, staff, and other interested parties.
Breaking news: FDA approves only once-daily LABA for COPD
July 5th 2011FDA has approved once-daily indacaterol inhalation powder (Arcapta Neohaler, Novartis) 75 µg for the long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Arcapta is not indicated for acute deteriorations of COPD or to treat asthma.
FDA's Hamburg to make final decision on Avastin's indication for metastatic breast cancer
July 1st 2011In the face of dozens of pink-clad demonstrators at the gates of FDA and many heartfelt pleas from women with metastatic breast cancer, an advisory committee to the agency voted unanimously at the end of June to hold firm in its recommendation that approval for Avastin (bevacizumab) for breast cancer be withdrawn.
Crizotinib treatment for ALK+ NSCLC shows early promise
June 30th 2011Crizotinib, an investigational drug, demonstrated an association with a sharp increase in survival rates for patients with advanced non-small cell lung cancer (NSCLC) with an anaplastic lymphoma kinase (ALK) positive genetic alteration, according to the results of an early-phase study presented at the 2011 annual meeting of the American Society of Clinical Oncology.
Intensive-dose statin therapy may increase diabetes risk
June 30th 2011Compared with moderate-dose therapy, intensive-dose statin therapy appears to be associated with increased risk of new-onset diabetes, concluded a meta-analysis of data from 5 statin trials published in the June 22/29 issue of JAMA.